Discovering Markers Of Disease Progression In Patients With Ms Treated With Natalizumab

Discovering markers of disease progression in patients with MS treated with natalizumab

Researchers discover first genetic marker for severity of Multiple Sclerosis

Al Jazeera English

Bench to Bedside: Multiple Sclerosis and Tysabri, Part 1 - Ted Yednock

Science Communication Lab

Cognitive relapses as markers of disease progression in MS

Surrogate Markers for MS

Additional Insights from Natalizumab Treatment in MS

Gavin Giovannoni

A Worse MS Prognosis?

Aaron Boster MD

Benefits of SC natalizumab in MS

Doctors have made a new discovery in multiple sclerosis gene markers

Bench to Bedside: Multiple Sclerosis and Tysabri, Part 2 - Ted Yednock

Science Communication Lab

How is Tysabri Used in MS?

Multiple Sclerosis Foundation

The future of biomarkers in MS: novel discoveries and defining protocols

Safely switching from natalizumab to ocrelizumab in patients with MS at risk of PML

Dr Paul Molyneux - Managing PML risk in patients treated with Natalizumab.

At the Limits - Leading Medical Education

What You Need to Know About Natalizumab (Tysabri®)

National MS Society

Updates on natalizumab and anti-CD20 antibodies for MS

Evaluating Natalizumab’s Risk-Benefit Profile in MS

Natalizumab improves mental and social health in a real-world MS cohort

Markers of biological aging predict disability development in MS

Tysabri: A Game-Changer in Multiple Sclerosis Treatment - What You Need to Know